Galmed Pharmaceuticals Ltd. (GLMD)

NASDAQ: GLMD · IEX Real-Time Price · USD

0.285

-0.003 (-0.94%)

At close: Jul 2, 2024, 3:55 PM

0.303

+0.018 (6.20%)

After-hours: Jul 2, 2024, 7:59 PM EDT

Galmed Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2012
Selling, General & Admin	3.92	4.66	5.66	4.13	4.2	Upgrade
Research & Development	3.57	13	27.22	26.08	18.18	Upgrade
Operating Expenses	7.49	17.65	32.88	30.21	22.38	Upgrade
Operating Income	-7.49	-17.65	-32.88	-30.21	-22.38	Upgrade
Interest Expense / Income	-0.58	0.22	-0.41	-1.44	-1.92	Upgrade
Pretax Income	-6.91	-17.87	-32.47	-28.77	-20.46	Upgrade
Net Income	-6.91	-17.87	-32.47	-28.77	-20.46	Upgrade
Shares Outstanding (Basic)	3	2	2	1	1	Upgrade
Shares Outstanding (Diluted)	3	2	2	1	1	Upgrade
Shares Change	65.23%	2.22%	15.59%	0.79%	16.41%	Upgrade
EPS (Basic)	-2.50	-10.65	-19.80	-20.25	-14.55	Upgrade
EPS (Diluted)	-2.50	-10.65	-19.80	-20.25	-14.55	Upgrade
Free Cash Flow	-6.14	-18.51	-32.9	-26.33	-14.95	Upgrade
Free Cash Flow Per Share	-2.22	-11.04	-20.07	-18.56	-10.62	Upgrade
EBITDA	-7.46	-17.62	-32.84	-30.17	-22.34	Upgrade
Depreciation & Amortization	0.03	0.04	0.04	0.04	0.04	Upgrade
EBIT	-7.49	-17.65	-32.88	-30.21	-22.38	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).